CD8A and neoplasm: Subsequent validation in this and other melanoma models confirmed that Activin-A secretion by melanoma cells impairs adaptive anti-tumor immunity and the response to adoptive T cell transfer and immune checkpoint blockade therapies, correlating with an indirect inhibitory effect on tumor infiltration by cytotoxic CD8+ T cells10.